CJC-1295: Mechanism, Evidence, and Regulatory Status

CJC-1295 is a synthetic GHRH analog: a lab-made molecule that mimics growth-hormone-releasing hormone and prompts your pituitary to release more of your own growth hormone. It is not FDA-approved, its human evidence is limited to early-stage studies, and as of late 2024 the FDA's advisory committee voted against it for compounding. It is also banned in sport at all times.

This article explains how CJC-1295 works, the important difference between the DAC and no-DAC versions, what the (thin) evidence actually shows, and why any use belongs with a licensed provider. Nothing here is a dosing guide or a recommendation to use it.

What CJC-1295 is

To understand CJC-1295, start with the system it targets. Your hypothalamus releases GHRH (growth-hormone-releasing hormone), which tells the pituitary to secrete growth hormone (GH) in pulses. GH then drives production of IGF-1 (insulin-like growth factor 1) in the liver, and IGF-1 mediates many of GH's downstream effects.

CJC-1295 is a modified version of GHRH. It binds the same pituitary receptors and amplifies GH release, working with your own machinery rather than injecting GH directly. That distinction matters: it is a secretagogue (something that prompts secretion), not a hormone replacement. Our growth hormone peptides explained piece lays out how GHRH analogs differ from other classes.

DAC vs no-DAC: the distinction that changes everything

The single most important thing to understand about CJC-1295 is that "CJC-1295" can mean two genuinely different compounds.

CJC-1295 with DAC includes a drug affinity complex that covalently binds to albumin in the blood. This extends the half-life from the minutes that native GHRH lasts to roughly 6 to 8 days. The result is a sustained elevation of GH and IGF-1 rather than the natural pulsatile pattern. Some argue this constant elevation is actually less physiologic than the body's normal rhythm.

CJC-1295 without DAC, often sold as "modified GRF 1-29" or "Mod GRF," lacks that albumin-binding modification and has a half-life of about 30 minutes. It is effectively a separate compound: different dosing frequency, different pharmacokinetics, more pulsatile in effect. Treating the two as one product is a common and consequential error.

The table below frames the distinction conceptually. It is not a dosing protocol.

Property	CJC-1295 with DAC	CJC-1295 without DAC (Mod GRF 1-29)
Half-life	~6 to 8 days	~30 minutes
GH/IGF-1 pattern	Sustained elevation	More pulsatile, short-lived
Practical implication	Less frequent administration	More frequent administration
How physiologic	Less (continuous elevation)	Closer to natural pulsing
Evidence	Phase I/II data (DAC version) exists	Even more limited

The reason this distinction is dosing-frequency-sensitive matters for tracking: a multi-day half-life and a 30-minute half-life imply completely different schedules, and getting them confused is a real error.

What the evidence actually shows

Here is the honest state of the science. The strongest published human data for CJC-1295 is a 2006 Phase I/II study (Walker et al., J Clin Endocrinol Metab, n=65) showing dose-dependent increases in GH and IGF-1 in healthy adults, sustained for about 6 days after a single dose of the DAC version. That is a real, published result, and it confirms the compound does what its mechanism predicts to hormone levels.

What does not exist is the part people actually care about: there are no Phase III trials, no approved indication, and no long-term human safety data. The popular claims, body recomposition, anti-aging, faster recovery, muscle gain, fat loss, are all off-label and largely extrapolated from mechanism, not demonstrated in outcome trials. "Raises GH and IGF-1" is established; "meaningfully changes your body composition safely over years" is not.

Regulatory status

CJC-1295 is not FDA-approved for any indication. Its compounding status is worse than some other research peptides: the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against CJC-1295 at both October and December 2024 meetings, meaning it does not currently have a clear path to legal 503A compounding through licensed pharmacies. Practically, that pushes it firmly into research-chemical territory.

It is also explicitly banned in sport. The WADA 2026 Prohibited List names CJC-1295 (and CJC-1293) as prohibited GHRH analogs under category S2, banned at all times, in and out of competition (WADA 2026; BSCG). If you are a tested athlete, this is disqualifying regardless of dose or intent.

Because it circulates through unregulated vendors, counterfeit and contaminated product is a genuine risk, and purity, sterility, and endotoxin levels cannot be assumed without third-party testing.

Common reported uses (none of them approved)

It is worth naming the goals people actually pursue with CJC-1295, precisely so they can be set against the evidence. The compound is marketed and discussed for GH and IGF-1 elevation aimed at body recomposition, anti-aging, improved recovery and sleep, muscle gain, and fat loss. Every one of these is off-label and unapproved, and none is backed by an outcome trial showing CJC-1295 delivers it safely.

This is the crux of responsible reading on the topic. The mechanism makes these outcomes plausible: more GH and IGF-1 could, in principle, nudge body composition and recovery. But plausibility is where the supplement-marketing world lives, and the gap between "could in principle" and "demonstrated in a controlled human trial" is enormous for CJC-1295. The single published efficacy-relevant study measured hormone levels, not real-world outcomes like strength, fat mass, or healthspan. Anyone presenting CJC-1295 results as established is extrapolating well beyond the data.

Why the DAC version's "convenience" cuts both ways

The long half-life of CJC-1295 with DAC is usually pitched as a benefit: fewer injections, a smoother schedule. That is genuinely more convenient. But the same property has a downside that often goes unmentioned.

Native GH release is pulsatile, coming in bursts, and that rhythm is part of normal physiology. The DAC version's multi-day half-life produces a sustained, continuous elevation of GH and IGF-1 instead of pulses, which is arguably less physiologic than what your body does on its own or what a short-acting secretagogue produces. Some researchers consider this continuous elevation a theoretical concern rather than a feature, because the body's own systems are tuned to a pulsing signal. So "fewer injections" and "more like nature" are not the same thing here; the convenient version is in some ways the less natural one. This is exactly the kind of tradeoff a provider should weigh rather than a marketing page.

Safety considerations

The reported and theoretical risks cluster into a few groups:

• Fluid retention and carpal-tunnel-like symptoms (numbness, tingling), consistent with the GH axis.
• Glucose elevation, relevant for anyone with prediabetes or diabetes.
• IGF-1 and cancer concern. Raising IGF-1 could, in theory, stimulate growth of a pre-existing malignancy. This is a class-wide concern for GH-axis agents and a key reason providers screen carefully before considering any of these compounds.
• Sourcing risk. Gray-market product of unknown quality is arguably the most concrete day-to-day hazard.

How CJC-1295 compares to other GHRH peptides

CJC-1295 is one of several GHRH analogs, and placing it next to its cousins clarifies what is and is not special about it.

Sermorelin is the older, shorter GHRH fragment (the first 29 amino acids of GHRH) with a half-life of roughly 10 to 20 minutes. It was actually FDA-approved in the past, under the brand names Geref Therapeutic and Geref Diagnostic, before the manufacturer voluntarily withdrew it commercially in 2008 for business reasons. That prior-approval history gives sermorelin a somewhat more settled compounding pathway than CJC-1295, which is part of why it still shows up in clinic protocols. Our sermorelin guide covers that nuance.

Tesamorelin is the one GHRH analog that is genuinely FDA-approved today, but only for a specific indication: reducing excess visceral fat in people with HIV-associated lipodystrophy. Its approval does not transfer to general body recomposition, and using it off-label for that is exactly that, off-label.

CJC-1295 sits apart from both: no current approval, no clear compounding path after the 2024 advisory votes, and a defining feature (the optional DAC modification) that makes its half-life either very long or very short depending on the version. It is the analog with the most pharmacologically dramatic range and the least settled legal status.

Why it is paired with ipamorelin

CJC-1295 is almost never discussed alone. It is typically paired with ipamorelin, a ghrelin-mimetic GH secretagogue that acts through a separate receptor pathway. The theory is that combining a GHRH analog (CJC-1295) with a ghrelin mimetic (ipamorelin) produces a larger, synergistic GH pulse than either alone. There are, however, no combined human trials, so this remains a mechanistic rationale rather than a proven protocol. Our ipamorelin guide and the dedicated CJC-1295 and ipamorelin stack article cover the pairing in detail.

What to ask a provider

Given the thin evidence and the cancer-related screening concern, any consideration of CJC-1295 should run through a licensed clinician. Useful questions:

• Am I getting the DAC or no-DAC version, and how does that change the schedule and the effect?
• What screening (including malignancy history) should happen before considering a GH-axis compound?
• Given that there are no Phase III trials or long-term safety data, what am I actually signing up for?
• What is the current FDA compounding and WADA status, and does either rule me out?

Where Myo fits

GHRH peptides are unusually schedule-sensitive: a DAC version with a multi-day half-life and a no-DAC version dosed far more often are not the same routine, and mixing them up is exactly the kind of error tracking is meant to prevent. If a provider prescribes a protocol, Myo's reminders and injection log keep the prescribed cadence on track without mental math, and the reconstitution calculator handles the concentration when a vial needs mixing, so your log reflects what you actually administered.

For anyone whose underlying goal is body composition, the more important point is that GH peptides are a small, unproven adjunct next to the proven drivers. Our complete guide to GLP-1 and muscle loss covers how protein and resistance training, the things that actually move lean mass, are where the leverage is, and Myo trends those alongside any provider-directed peptide so you can see whether anything is genuinely changing.

The bottom line: CJC-1295 reliably raises GH and IGF-1, but it is not FDA-approved, has no path to legal compounding as of late 2024, is banned in sport, and rests on early evidence with no long-term safety data. The DAC versus no-DAC distinction is essential, and any use belongs with a provider.

References

• Walker RF et al. (2006). Sustained increases in GH and IGF-1 following a single dose of CJC-1295 with DAC. J Clin Endocrinol Metab.
• Lexology. FDA 503A Peptide Update (CJC-1295 and ipamorelin PCAC votes). https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d
• BSCG. CJC-1295 Use in Sports and Military Rules Explained. https://www.bscg.org/blogs/single/cjc-1295-use-in-sports-and-military-rules-explained
• WADA. 2026 Prohibited List. https://www.wada-ama.org/en/prohibited-list
• FDA. Pharmacy Compounding Advisory Committee Briefing Document. https://www.fda.gov/media/183819/download